Evaluation of the Effectiveness and Impact of Nirsevimab Administered as Routine Immunization
Federico Martinón Torres
42,000 participants
Sep 25, 2023
OBSERVATIONAL
Conditions
Summary
A longitudinal observational study based on routinely collected data on hospital and health care use for RSV infections will be undertaken. The Galician public health registries will be used for data collection including baseline information and follow-up data. Historical data will be retrieved for comparison purposes. The study aims to observe and analyze data from all the eligible children in Galicia for nirsevimab treatment. The number of eligible children is expected to be approximately 14,000 per each RSV season.
Eligibility
Inclusion Criteria1
- Subjects born in Galicia from April 1st, 2023 and March 1st, 2026
Exclusion Criteria1
- No specific criteria has been reported
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Nirsevimab will be administered administered in a single dose at birth for birth cohort and at the beginning of the campaign for the other cohorts under study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06180993